Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.81 USD
Change Today -0.20 / -2.50%
Volume 717.3K
TROV On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

trovagene inc (TROV) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/15 - $13.58
52 Week Low
08/1/14 - $2.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TROVAGENE INC (TROV)

trovagene inc (TROV) Related Bloomberg News

View More Bloomberg News

trovagene inc (TROV) Related Businessweek News

No Related Businessweek News Found

trovagene inc (TROV) Details

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It is developing PCM BRAF and KRAS mutation detection tests for detecting mutations in metastatic cancer patients; and HPV HR detection test to detect the presence of various HPV genotypes using a urine sample. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

31 Employees
Last Reported Date: 03/12/15
Founded in 1999

trovagene inc (TROV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $539.0K
Chief Financial Officer
Total Annual Compensation: $338.8K
Chief Scientific Officer
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2014.

trovagene inc (TROV) Key Developments

Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform

Trovagene, Inc. announced the launch of a study that aims to determine utility of the company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 inhibitor, and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study will be led by researchers at Memorial Sloan Kettering Cancer Center (MSK). BRAF and NRAS oncogene mutations will be used as biomarkers to monitor tumor dynamics in treated patients. Primary objectives of the study include determining if circulating tumor (ctDNA) can determine response to therapy early, and if ctDNA results correlate with the clinical course of disease. The need to quantitatively monitor early response to cancer immunotherapy is widely recognized given the lack of response biomarkers, toxicities with combination immunotherapy, and the challenge of pseudo-progression, which is characterized by initial tumor swelling that is observed with traditional imaging tools.

TrovaGene, Inc.(NasdaqCM:TROV) added to Russell 2000 Index

TrovaGene, Inc. will be added to Russell 2000 Index

TrovaGene, Inc.(NasdaqCM:TROV) added to Russell 3000 Index

TrovaGene, Inc. will be added to the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TROV:US $7.81 USD -0.20

TROV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $19.74 USD -0.85
Genomic Health Inc $26.34 USD -0.28
Laboratory Corp of America Holdings $125.62 USD -0.70
Natera Inc $18.13 USD -0.08
Veracyte Inc $11.13 USD -0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation TROV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 590.0x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 600.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TROVAGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at